World Journal of Pharmaceutical and Medical Research (WJPMR) has indexed with various reputed international bodies like : Google Scholar , Index Copernicus , SOCOLAR, China , Indian Science Publications , Cosmos Impact Factor , Research Bible, Fuchu, Tokyo. JAPAN , Scientific Indexing Services (SIS) , UDLedge Science Citation Index , International Impact Factor Services , International Society for Research Activity (ISRA) Journal Impact Factor (JIF) , International Innovative Journal Impact Factor (IIJIF) , Scientific Journal Impact Factor (SJIF) , Global Impact Factor (In Process) , Digital Online Identifier-Database System (DOI-DS) , Science Library Index, Dubai, United Arab Emirates , Eurasian Scientific Journal Index (ESJI) , International Scientific Indexing, (ISI) UAE , IFSIJ Measure of Journal Quality , 

World Journal of Pharmaceutical
and Medical Research

An International Peer Reviewed Journal for Pharmaceutical and Medical Research and Technology
An Official Publication of Society for Advance Healthcare Research (Reg. No. : 01/01/01/31674/16)
ISSN 2455-3301
IMPACT FACTOR: 4.639

ICV : 78.6

Abstract

TUMOUR INFILTRATING LYMPHOCYTES AS A PROGNOSTIC AND PREDICTIVE FACTOR FOR NEOADJUVANT CHEMOTHERAPY IN TRIPLE NEGATIVE BREAST CANCER

Rana Saeed El-Sayed Ata, Lamiss Mohamed Abd El-Aziz, Ayman Mohamed El-Saqa MD and Asmaa Mohamed El-Kady*

ABSTRACT

Background: Triple negative breast cancer is a subtype of breast cancer that shows minimal or no immunohistochemical expression of estrogens receptor, progesterone receptor and human epidermal growth factor receptor 2 (HER2), & accounts for ~12% of invasive breast cancers. Patients with TNBC who received carboplatin had a significant three-fold increased probability of pathological complete response if the breast cancer was lymphocytic predominant. The presence of CD8+ cells in the tumor infiltrate prior to the onset of neoadjuvant chemotherapy (NAC) predicted pCR in several studies. Aim: Comparison between paclitaxel and doxorubicin versus paclitaxel and carboplatin as neoadjuvant chemotherapy in triple negative breast cancer as regard treatment response, survival rates and toxicity analysis of different prognostic factors with special emphasis on tumour infiltrating lymphocytes (TILs) and their immunophenotyping profile as a prognostic and predictive marker. Patients and methods: This retrospective study included 40 patients with TNBC stage II, III treated with NAC at Clinical Oncology and Nuclear Medicine Department Tanta University Hospitals and Oncology Department of Health Insurance hospitals throughout the period from January 2011 to December 2015. Twenty patients were treated with paclitaxel and doxorubicin (Group A) while 20 patients were treated with paclitaxel and carboplatin (Group B). Results: Paclitaxel and carboplatin showed higher overall response (OAR) and pCR (90%, 40%) respectively vs (75%, 5%) for paclitaxel and doxorubicin. Five-year OS, DFS were higher in carboplatin, paclitaxel group. High TILs tumors showed higher pCR, 5-year OS and DFS versus low, moderate TILs tumors. Conclusion: Platinum-based chemotherapy drugs are more effective in TNBC as neoadjuvant chemotherapy. Increasing numbers of stromal TILs were associated with improved pCR, OS, DFS in TNBC. Increased stromal expressions of CD3 and CD8 were all significantly associated with pCR.

[Full Text Article]

Powered By WJPMR | All Right Reserved

WJPMR